Cost-Effectiveness of Certolizumab Pegol in the Treatment of Active Rheumatoid Arthritis, Axial Spondyloarthritis, and Psoriatic Arthritis in Romania
Value in Health- United Kingdom
doi 10.1016/j.jval.2014.08.2608
Full Text
Abstract
Available in
Date
November 1, 2014
Authors
Publisher
Elsevier BV